ACRX For The Long Haul, CLDX Disappoints, NVIV Inspires, MRNS Awaits Data

Shares of Celldex Therapeutics Inc. plunged more than 53% on Monday, following the company's decision to pull the plug on its phase III study of RINTEGA in newly diagnosed glioblastoma patients.

from RTT - Biotech http://ift.tt/1QDucw1
via IFTTT